| Literature DB >> 31755917 |
Karin Gehring1,2, Martijn M Stuiver3,4, Eva Visser5, Corelien Kloek6, Martin van den Bent7, Monique Hanse1, Cees Tijssen8, Geert-Jan Rutten1, Martin J B Taphoorn9,10, Neil K Aaronson11, Margriet M Sitskoorn2.
Abstract
BACKGROUND: Patients with glioma often suffer from cognitive deficits. Physical exercise has been effective in ameliorating cognitive deficits in older adults and neurological patients. This pilot randomized controlled trial (RCT) explored the possible impact of an exercise intervention, designed to improve cognitive functioning in glioma patients, regarding cognitive test performance and patient-reported outcomes (PROs).Entities:
Keywords: brain neoplasms; cognitive function; exercise; glioma; patient reported outcome measures
Mesh:
Year: 2020 PMID: 31755917 PMCID: PMC6954415 DOI: 10.1093/neuonc/noz178
Source DB: PubMed Journal: Neuro Oncol ISSN: 1522-8517 Impact factor: 12.300
NPA and PRO measures at baseline and follow-up
| Cognitive Performance Measures | ||||||
|---|---|---|---|---|---|---|
| Test | Abbreviation | Scores Used for Analysis (Score or Scale Range) | Domain Measured | |||
|
| ||||||
| Stroop Color-Word Test[ | SCWT-Int | Interference—ratio of the additional time needed for Card III relative to Card I (time) and II (time) | Attentional inhibition of a dominant response | |||
| Letter Digit Substitution Test[ | LDST-Read | 90 Sec Reading (number correct: 0–125) | Information processing speed | |||
| LDST-Write | 90 Sec Writing (number correct: 0–125) | Psychomotor and information processing speed | ||||
| WAIS-R Digit span[ | DS-Forw | Forward (span: 0–8) | Attention span | |||
| DS-Backw | Backward (span: 0–7) | Working memory | ||||
| Test of Everyday Attention[ | ElevCount-Distr | Elevator counting with Distraction (number correct: 0–10) | Auditory selective attention and working memory | |||
| TelSearch | Telephone Search task (time per target: 0–∞) | Sustained selective attention | ||||
| TelSearch-Count | Telephone Search while Counting (decrement in speed due to 2nd task) | Divided attention | ||||
|
| ||||||
| Visual Verbal Learning Test[ | VVLT-T1 | Trial 1 (number correct: 0–15) | Immediate verbal recall | |||
| VVLT-Tot | Total (number correct: 0–75) | Verbal learning | ||||
| VVLT-DelRec | Delayed Recall (number correct: 0–15) | Delayed verbal memory | ||||
| WMS-III Verbal Paired Associates[ | VPA-DiRecA | Direct Recall List A (number correct: 0–8) | Immediate verbal association memory | |||
| VPA-TotRec | Total Recall (number correct: 0–32) | Verbal association learning | ||||
| VPA-DelRec | Delayed Recall (number correct: 0–8) | Delayed verbal association memory | ||||
|
| ||||||
| Concept Shifting Test[ | CST-Shift | Additional time needed for CST-C above CST-A and CST-B | Alternating attention/shifting | |||
| GIT Letter Fluency[ | GIT-LF | LF (number correct: 0-∞) | Speed and flexibility of verbal thought process | |||
| GIT Category Fluency[ | GIT-CF | CF (number correct: 0-∞) | Speed and flexibility of verbal thought process and application of strategies | |||
| Test of Everyday Attention[ | ElevCount-Rev | Elevator counting with Reversal (number correct: 0–10) | Auditory working memory/shifting | |||
|
| ||||||
|
| ||||||
|
| ||||||
| MOS Cognitive Functioning Scale[ | CFS total | Total score (6–30) | Subjective cognitive function | |||
| Cognitive Failure Questionnaire[ | CFQ total | Total score (0–100) | Subjective cognitive failures in daily life | |||
|
| ||||||
| Multidimensional Fatigue Inventory[ | MFI-GF | General Fatigue (4–20) | General fatigue | |||
| MVI-PF | Physical Fatigue (4–20) | Physical fatigue | ||||
| MVI-RA | Reduced Activity (4–20) | Reduced activity | ||||
| MVI-RM | Reduced Motivation (4–20) | Reduced motivation | ||||
| MVI-MF | Mental Fatigue (4–20) | Mental fatigue | ||||
| Pittsburgh Sleep Quality Index[ | PSQI total | Total score (0–21) | Quality of sleep | |||
|
| ||||||
| Profile of Mood States[ | POMS total | Total score (22–120) | Mood | |||
|
| ||||||
| Brain-cancer specific HRQL questionnaire[ | QLQ-BN20 FU | Future Uncertainty (0–12) | Brain-cancer specific future uncertainty | |||
| QLQ-BN20 VD | Visual Disorder (0–9) | Brain-cancer specific visual disorder | ||||
| QLQ-BN20 MD | Motor Dysfunction (0–9) | Brain-cancer specific motor dysfunction | ||||
| QLQ-BN20 CD | Communication Deficit (0–9) | Brain-cancer specific communication deficit | ||||
| MOS Short-Form 36[ | SF-36 PCS | Physical Component Scale (0–100) | Mental health–related quality of life | |||
| SF-36 MCS | Mental Component Scale (0–100) | Physical health–related quality of life | ||||
∞: no upper limit.
Abbreviations: GIT, Groningen Intelligence Test. HRQL, health-related quality of life. MOS, Medical Outcomes Study. WAIS-R, Wechsler Adult Intelligence Scale–Revised. WMS-III, Wechsler Memory Scale III.
Fig. 1Flow of participants through the trial.
Baseline characteristics of participants with complete NPA1 and NPA2 data
| Characteristic | Exercise Group ( | Control Group ( |
|---|---|---|
| Age, y | ||
| mean (SD) | 49.2 (8.9) | 48.0 (11.9) |
| Female, | 12 (57) | 6 (55) |
| Education, | ||
| low | 2 (10) | 0 (0) |
| middle | 9 (43) | 6 (55) |
| high | 10 (47) | 5 (46) |
| WHO tumor grade, | ||
| II | 15 (71) | 6 (55) |
| III | 6 (29) | 5 (46) |
| Tumor histology, | ||
| astrocytoma | 6 (29) | 5 (46) |
| oligodendroglioma | 12 (57) | 5 (46) |
| oligoastrocytoma | 3 (14) | 1 (9) |
| Disease duration, y | 7.6 (5.0) | 8.5 (8.6) |
| mean (SD) | ||
| Left hemisphere, | 10 (48) | 4 (36) |
| Surgery, | ||
| biopsy | 2 (10) | 1 (9) |
| resection | 19 (90) | 9 (82) |
| Chemotherapy, | 8 (38) | 4 (36) |
| Radiotherapy, | 12 (57) | 5 (46) |
| Epilepsy, | 15 (71) | 8 (73) |
| Anti-epileptic drugs, | 12 (57) | 6 (55) |
| VO2 peak classification,[ | ||
| recreational (versus sedentary) | 4 (19) | 1 (9) |
| LDST-Write,[ | 43.4 (11.9) | 43.4 (10.0) |
Fig. 2Within-group mean/#median changes in Z scores for NPA and PRO measures. For all measures, positive changes indicate improvement in outcomes.
Between-group effects on NPA and PRO measures
| Cognitive Performance Measures | B [95% CI] | Patient-Reported Outcomes | B [95% CI] |
|---|---|---|---|
| Exercise Group | Exercise Group | ||
| Control Group | Control Group | ||
|
|
| ||
| SCWT-Int | +0.52 [0.05;0.99] | CFS total | +0.20 [−0.45;0.86] |
| LDST-Read | +0.47 [−0.16;1.10] | CFQ total | +0.04 [−0.52;0.60] |
| LDST-Write | +0.18 [−0.20;0.56] |
| |
| DS-Forw | +0.57 [−0.01;1.14] | MFI−GF | +0.14 [−0.43;0.71] |
| DS-Backw | −0.04 [−0.89;0.81] | MFI−PF | +0.52 [−0.23;1.27] |
| ElevCount-Distr | +0.51 [0.03;0.98] | MFI−RA | +0.63 [−0.17;1.43] |
| TelSearch | −0.47 [−1.43;0.49] | MFI−RM | +0.19 [−0.51;0.89] |
| TelSearch-Count | −0.13 [−0.81;0.55] | MFI−MF | 0.00 [−0.57;0.56] |
|
| PSQI total | +0.34 [−0.23;0.91] | |
| VVLT-T1 | +0.29 [−0.56;1.13] |
| |
| VVLT-Tot | +0.16 [−0.42;0.74] | POMS total | +0.50 [0.04;0.96] |
| VVLT-DelRec | +0.11 [−0.49;0.71] |
| |
| VPA-DiRecA | −0.02 [−1.13;1.10] | ||
| VPA-TotRec | +0.13 [−0.35;0.62] | SF36 PCS | −0.18 [−0.86;0.49] |
| VPA-DelRec | +0.14 [−0.20;0.48] | SF36 MCS | +0.63 [−0.16;1.41] |
|
| QLQ−BN20 FU | +0.08 [−0.52; 0.68] | |
| CST-Shift | +0.35 [−0.30;0.99] | QLQ−BN20 VD | +0.19 [−0.27; 0.66] |
| GIT-LF | −0.13 [−0.61;0.35] | QLQ−BN20 MD | +0.14 [−0.30; 0.59] |
| GIT-CF | +0.07 [−0.45;0.59] | QLQ−BN20 CD | −0.01 [−0.46; 0.45] |
| ElevCount-Rev | +0.25 [−0.23;0.73] |
Abbreviations: B, regression coefficient. CI, confidence interval.
Numbers of tests with reliably improved and reliably declined individuals in each group
| Reliable Improvement | Reliable Decline | ||||
|---|---|---|---|---|---|
| Exercise Group | Control Group | Exercise Group | Control Group | ||
| Number of test variables (standardized residuals) | 0 | 9 (−0.3) | 6 (0.4) | 12 (0.7) | 3 (−0.9) |
| 1 | 7 (0.2) | 3 (−0.2) | 5 (−0.6) | 5 (0.8) | |
| 2 | 1 (−0.7) | 2 (1.0) | 4 (0.0) | 2 (0.0) | |
| 3 | 2 (0.6) | 0 (−0.8) | 0 (−0.8) | 1 (1.1) | |
| 4 | 1 (0.4) | 0 (−0.6) | – | – | |
| 5 | 1 (0.4) | 0 (−0.6) | – | – | |
| Total | 21 | 11 | 21 | 11 |